Acquisition provides growth opportunities and increases synergies within the ProScan Family of Companies
ProScan Imaging, one an international radiology services group, has increased its majority ownership of WorldCare Clinical (WCC) LLC to 100 percent, aiming to position the organization for growth and increased synergies in technology, service offerings, expertise, and accredited educational programs to benefit their biopharmaceutical and device manufacturer customers.
“The acquisition allows us to more closely align WCC’s exceptional trial management and assessment accuracy and consistency testing methodology with ProScan’s world-wide medical image file exchange platform and its international teleradiology assets,” stated Michael O’Brien, President and COO of the ProScan Family of Companies. “The enhanced service delivery model will allow WCC’s customers to lower their trial costs, while flexibly accessing the most appropriate independent expert assessment team.”
“Our access to large groups of sub-specialty trained, practicing radiologists and clinicians at ProScan and Harvard teaching hospitals coupled with our rapid turnaround global teleradiology and telemedicine endpoint assessment committees (EACs), all uniquely position us to take advantage of the ever changing and more rigorous clinical trial requirements,” stated Dr. Richard Walovitch, President of WCC. “As the number of stakeholders involved in product life cycle management increases, WCC can provide continuity and efficiency of service, effective efficacy and safety evaluation, reporting, and continuing medical education, informing these stakeholders on the best path for their product from early clinical trial activity through commercialization.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.